Our Pricing

Wegovy vs Saxenda: Clinical Comparison for UK Patients

When comparing Wegovy vs Saxenda, UK patients often ask which injectable weight loss treatment delivers better results. Both are licensed GLP-1 receptor agonists approved by the MHRA for chronic weight management, but they differ significantly in active ingredient, dosing frequency, clinical efficacy, and cost. This evidence-based guide examines how Wegovy (semaglutide) and Saxenda (liraglutide) compare across key clinical parameters to help you make an informed choice with your prescriber.

How Wegovy vs Saxenda Differ in Active Ingredient and Mechanism

The fundamental difference in the Wegovy vs Saxenda comparison lies in their active pharmaceutical ingredients. Wegovy contains semaglutide, a longer-acting GLP-1 receptor agonist with a half-life of approximately one week, whilst Saxenda contains liraglutide, which has a half-life of around 13 hours [1]. Both medications mimic the naturally occurring glucagon-like peptide-1 hormone, which regulates appetite and food intake by acting on receptors in the brain and gastrointestinal tract.

This pharmacokinetic difference translates directly into dosing convenience. Wegovy requires just one subcutaneous injection per week, whereas Saxenda must be administered daily [2]. For many UK patients, the once-weekly regimen of Wegovy offers superior adherence and convenience, though individual preference and lifestyle factors should guide this decision in consultation with your prescriber. Both treatments work by slowing gastric emptying, reducing hunger signals, and increasing feelings of fullness after meals.

Wegovy vs Saxenda: Clinical Trial Evidence and Weight Loss Results

Head-to-head clinical data strongly favours Wegovy in the efficacy dimension of the Wegovy vs Saxenda debate. In the landmark STEP 1 trial, participants using semaglutide 2.4mg (Wegovy) achieved an average weight reduction of 14.9% from baseline over 68 weeks, compared to 2.4% with placebo [3]. By contrast, the SCALE Obesity trial demonstrated that Saxenda users lost an average of 8.0% body weight over 56 weeks versus 2.6% with placebo [4].

These results suggest that Wegovy may deliver nearly twice the weight loss of Saxenda in clinical trial settings, though individual responses vary considerably. A 2022 network meta-analysis comparing GLP-1 agonists for weight management confirmed semaglutide's superior efficacy profile across multiple endpoints [5]. However, it's important to note that both medications are effective tools when combined with a reduced-calorie diet and increased physical activity, and either may be appropriate depending on your medical history, tolerability, and prescriber recommendation.

Real-World Effectiveness in UK Clinical Practice

Beyond controlled trials, UK prescribers report that real-world outcomes with Wegovy vs Saxenda align broadly with trial data, though adherence and individual metabolic factors significantly influence results. Patients who maintain consistent injection schedules and implement sustainable lifestyle modifications tend to achieve the best outcomes with either treatment. Our clinical team at Cured Pharmacy works with hundreds of UK patients monthly, and we've observed that treatment choice often depends on balancing efficacy expectations with tolerability, cost considerations, and injection frequency preference.

Side Effect Profile: Wegovy vs Saxenda Tolerability

When evaluating Wegovy vs Saxenda for tolerability, both medications share a similar side effect profile characteristic of GLP-1 receptor agonists. The most commonly reported adverse effects include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, particularly during dose escalation phases [1][3]. In clinical trials, approximately 44% of Wegovy users and 39% of Saxenda users experienced nausea, though this typically diminishes as the body adapts to treatment.

The key difference lies in dosing titration strategy. Wegovy follows a gradual monthly dose escalation over 16-20 weeks to the maintenance dose of 2.4mg weekly, which helps minimise gastrointestinal side effects [2]. Saxenda similarly employs weekly dose increases over five weeks to the 3.0mg daily maintenance dose [4]. Some UK patients find the daily injection routine of Saxenda allows for more flexible dose adjustment if side effects emerge, whilst others prefer Wegovy's less frequent dosing. Serious adverse events are rare with both treatments, but both carry warnings regarding thyroid C-cell tumours based on rodent studies, and neither should be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Wegovy vs Saxenda UK Pricing and Value Comparison

Cost is a significant factor in the Wegovy vs Saxenda decision for UK patients, as neither medication is routinely available on NHS prescription for weight management outside specialist services. At Cured Pharmacy, Saxenda starts from £69.00 per pen, whilst Wegovy starts from £69.00 per pen, both subject to clinical assessment by our UK-registered prescribers. When calculating monthly costs, Saxenda typically requires five pens per month (one daily injection), whereas Wegovy requires four pens per month (one weekly injection).

On a per-treatment-cycle basis, Wegovy often represents better value when factoring in the superior average weight loss demonstrated in clinical trials. However, individual budgets and insurance coverage vary, and some patients may find Saxenda's lower starting price per pen more accessible initially. Our transparent pricing model shows all costs upfront before your consultation, and new patients can Save £20 off their first order using code Weightlossnew. All prescription weight loss treatments at Cured Pharmacy include a free online consultation with a UK prescriber, completed in under three minutes, with next-day discreet delivery available across the UK.

Long-Term Cost Considerations

When comparing Wegovy vs Saxenda over a six-month or twelve-month treatment course, the cumulative cost difference narrows when accounting for efficacy. Patients achieving target weight loss more quickly with Wegovy may require fewer total months of treatment, though maintenance therapy is often recommended to sustain results. Your prescriber will discuss the most cost-effective treatment duration based on your individual weight loss goals and response to therapy.

Dosing and Administration: Wegovy vs Saxenda Practical Differences

The practical administration differences between Wegovy vs Saxenda significantly impact treatment adherence and patient satisfaction. Wegovy is supplied in pre-filled, single-dose pens containing 0.25mg, 0.5mg, 1.0mg, 1.7mg, or 2.4mg of semaglutide, administered once weekly on the same day each week [2]. Patients inject subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites to minimise local reactions.

Saxenda comes in a multi-dose pen containing 18mg of liraglutide, delivering 3mg per pen over six days when used at the maintenance dose of 3.0mg daily [4]. This requires daily injections and careful pen management to ensure adequate supply. Some UK patients appreciate the flexibility of daily dosing to adjust timing around meals or activities, whilst others find weekly Wegovy injections easier to remember and integrate into their routine. Both medications require refrigeration before first use, though Wegovy pens can be stored at room temperature for up to 28 days after opening, and Saxenda pens for 30 days. Our pharmacy team provides full administration training resources with every prescription to ensure confident, correct technique.

Who Should Choose Wegovy vs Saxenda: Clinical Suitability

Determining whether Wegovy vs Saxenda is more appropriate requires individualised clinical assessment by a UK prescriber. Both medications are licensed for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidaemia [1][4]. NICE guidance supports the use of GLP-1 receptor agonists for weight management in patients meeting these criteria when lifestyle interventions alone have been insufficient.

Wegovy may be particularly suitable for patients seeking maximum weight loss efficacy and who prefer once-weekly dosing convenience. Saxenda might be considered for those who have previously used liraglutide formulations, prefer daily injection routines, or have cost constraints that make the lower per-pen price more accessible initially. Certain medical conditions contraindicate both treatments, including pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma, diabetic ketoacidosis, and severe gastrointestinal disease. Your prescriber will review your complete medical history, current medications, and weight loss goals to recommend the most appropriate option. At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team ensure every prescription meets UK regulatory standards and is genuinely suitable for the individual patient.

Switching Between Treatments

Some patients may start with Saxenda and later switch to Wegovy, or vice versa, based on efficacy, tolerability, or cost factors. Such transitions should always be managed by your prescriber, who will determine appropriate dose adjustments and washout periods if needed. The Wegovy vs Saxenda choice is not necessarily permanent, and treatment plans can be adapted as your weight loss journey progresses and circumstances change.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Electronic Medicines Compendium. (2022). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Novo Nordisk Limited. [accessed 15 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 15 August 2026]
5. Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., ... & Lytvyn, L. (2022). Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. The Lancet, 399(10321), 259-269. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.